Managed Healthcare Executive6d
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...
Medscape6d
FDA Approves Fourth Denosumab Biosimilar
Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...
Healio6d
FDA grants approval to two more denosumab biosimilars
The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...
PipelineReview.com6d
Fresenius Receives FDA Approval for their Denosumab Biosimilars and Secures Global Settlement Agreement
LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...
JD Supra5d
FDA Approves Fresenius’s Denosumab Biosimilars
On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...
Le Lézard6d
Newport Healthcare Releases 2024 Outcomes Report Highlighting Significant Patient Improvements in Mental Health Treatment
Newport Healthcare, a national network of evidence-based mental health treatment programs for adolescents and young adults, today announced key findings from its 2024 outcomes report, The Science of ...
Le Lézard6d
seca Unveils First-Of-Its-Kind ?Treatment Tracker' to Directly Link Patient Treatment Plans with Body Composition Data
Treatment Tracker. This first-of-its-kind solution integrates a patient's treatment plan with their body composition results on a ...
Center for Biosimilars6d
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...